Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 17/20 | 0.45 |
| ▸ | ERBB2 | P04626 | 15/20 | 0.45 |
| ▸ | ERBB4 | Q15303 | 4/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.38 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24167465 | 0.92 | EGFR (0.41) | EGFRERBB2ERBB4JAK3NPC1 | |
| SCHEMBL24167802 | 0.90 | EGFR (0.46) | EGFRERBB2ERBB4JAK3NPC1 | |
| SCHEMBL24167452 | 0.90 | EGFR (0.50) | EGFRERBB2 | |
| SCHEMBL24167456 | 0.88 | EGFR (0.60) | EGFRERBB2ERBB4 | |
| SCHEMBL24167863 | 0.87 | EGFR (0.45) | EGFRERBB2ERBB4JAK3NPC1 | |
| SCHEMBL24167208 | 0.86 | EGFR (0.43) | EGFRERBB2ERBB4JAK3NPC1 | |
| SCHEMBL24168128 | 0.86 | EGFR (0.54) | EGFRERBB2ERBB4JAK3KDM4E | |
| SCHEMBL24167848 | 0.85 | EGFR (0.47) | EGFRERBB2ERBB4JAK3NPC1 | |
| SCHEMBL24168149 | 0.83 | EGFR (0.48) | EGFRERBB2ERBB4JAK3NPC1 | |
| SCHEMBL24167467 | 0.81 | EGFR (0.49) | EGFRERBB2ERBB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265098-A1 | ALKYNE QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230265098-A1 | ALKYNE QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN INC. | 2023-08-24 | — | — | US | disclosed |
| WO-2022006386-A1 | ALKYNE QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN THERAPEUTICS, INC. (US) | 2022-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265098-A1 | ALKYNE QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ERBB2, ERBB3, CHEK2 | EGFR 6/4885ERBB2 1/4885ERBB4 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.